Both IL-17A and IL-17F are expressed in psoriasis lesional skin and have the ability to synergise with other cytokines to amplify inflammation. This is the pathogenetic rationale to block IL-17F in addition to IL-17A. Bimekizumab is an antibody that neutralises the biologic function of both.
In the original 12-week BE ABLE 1 study previously presented, therapy with bimekizumab led to rapid, substantial clinical improvements in patients with moderate-to-severe plaque psoriasis [2]. More than 70% of patients treated with 160, 320, or 480 mg bimekizumab reached an improvement of the PASI by 90% (PASI90 response) in this trial. At this year´s AAD meeting, results were presented of the phase 2b extension study BE ABLE 2 after 60 weeks of follow-up [6]. In this extension, almost all patients who initially had PASI90/100 with bimekizumab maintained the responses during 60 weeks of follow-up. Similarly, patients who switched from placebo to bimekizumab and attained PASI90/100 responses maintained the status long-term. Across all doses evaluated in the study, 80-100% of responding patients remained in response at 60 weeks. "We have not seen responses like this," said Dr Andrew Blauvelt (Oregon Medical Research Center, USA). "In addition, we have a consistent safety profile, as would be expected with an IL-17 blocker. These results really support the view that IL-17A and IL-17F blockade is useful in psoriasis."
The most frequent treatment-emergent adverse events were oral candidiasis and nasopharyngitis (13% each). All cases of oral candidiasis were localised, superficial infections of mild or moderate intensity that resolved with standard treatment. No serious treatment-emergent adverse events occurred in more than one patient. These results validate dual neutralisation of IL-17A and IL-17F as a new therapeutic approach, which might result in slightly improved efficacy compared with IL-17A blockade alone.
1. Blauvelt A. Abstract 11180, AAD Annual Meeting, 1-5 March 2019, Washington DC, USA.
2. Papp K, et al. J Am Acad Dermatol 2018; 79:279-86.
Posted on
Previous Article
« Pemphigus patients prone to osteoporosis Next Article
Plaque psoriasis – Efficacy of guselkumab »
« Pemphigus patients prone to osteoporosis Next Article
Plaque psoriasis – Efficacy of guselkumab »
Table of Contents: AAD 2019
Featured articles
Letter from the Editor
Interview with AAD president Prof. George J. Hruza
Late-Breakers
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Bermekimab – a future treatment for atopic dermatitis?
JAK1/2 inhibitor effective in alopecia areata
Novel anti-IgE drug enables durable urticaria control
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Thicker AK lesions benefit from laser pretreatment with high channel density
New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials
Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris
Serlopitant reduces pruritus associated with psoriasis
Atopic Dermatitis: Many New Therapies in the Pipeline
New and emerging atopic dermatitis therapies
Food triggers eczema – an imperturbable belief of patients
Psoriasis and Biologics: The Beat Goes On
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
JAK inhibitors: a new therapeutic tool for dermatologists
JAK inhibitors: a pathogenesis-directed therapy for alopecia areata
Can JAK inhibitors close the current therapeutic gap in AD?
Hair Loss: No Reason for Therapeutic Nihilism
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
Vitiligo in children
Surgical treatment for selected vitiligo cases
JAK-inhibitors: an emerging treatment option for vitiligo
What's New and Hot in Acne
Should we use more hormonal therapy?
Pearls of the Posters
Pemphigus patients prone to osteoporosis
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma
Related Articles
November 19, 2021
Durable intracranial responses with nivolumab/ipilimumab
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy